Unmet Medical Need

Laval – November 06, 2026 -- Only 62.0% of patients hospitalized with severe alcohol-associated hepatitis (AH) in the United States were estimated to survive 12 months, according to a real-world study from Bausch Health Companies Inc. and its gastroenterology unit, Salix Pharmaceuticals.

Study of 1,630 US adults tracks rehospitalization and transplant rates

The companies are presenting the poster, "Clinical Burden and Outcomes in a Large Real-World Cohort of Patients Hospitalized with Severe Alcohol-Associated Hepatitis," at the American Association for the Study of Liver Diseases' The Liver Meeting 2026. The meeting runs November 5-9 in Denver, Colorado. The cohort comprised 1,630 adults.

Rehospitalization climbs from 31.4% at 30 days to 69.1% at 12 months

Within 30 days of discharge, 31.4% of patients were rehospitalized. The estimated rate reached 69.1% by 12 months. The estimated liver transplantation rate at 12 months was 8.5%.

HANGZHOU – November 04, 2026 -- TJ Biopharma's GM-CSF antibody plonmarlimab achieved an 83.3% overall response rate at Week 8 in the Phase 2 PRIME-1 study of macrophage activation syndrome (MAS), according to results now published in the Journal of Hematology & Oncology.

PRIME-1 enrolled 18 patients who had failed high-dose glucocorticoids

The open-label, single-arm, multi-center study treated patients who were refractory to, or had relapsed after, high-dose glucocorticoid therapy. Fifteen of 18 patients achieved a complete or partial response. Median time to response was 2.1 weeks, with the earliest response recorded on Day 5.